Pritelivir for the Treatment of Nucleoside Analogue-Resistant Orolabial Herpes Simplex Virus 2 in a Person Living with HIV. (PubMed, J Assoc Med Microbiol Infect Dis Can) - Jul 11, 2025 - "The patient received multiple treatment courses including nucleoside analogue therapy, topical and intravenous foscarnet and cidofovir, and topical imiquimod but these failed to establish a significant and durable therapeutic response...Subsequent genotyping revealed a M183X mutation in UL23 expected to convey resistance to acyclovir and penciclovir...Pritelivir is a novel helicase-primase inhibitor that appears to be an attractive option for management of resistant herpes simplex infections due to its unique mechanism, excellent oral bioavailability, and minimal toxicity. To our knowledge, this is the first described case of treatment of nucleoside analogue-resistant orolabial herpes simplex 2 infection with pritelivir and the first documented use of pritelivir in Canada."
Journal • Herpes Simplex • Human Immunodeficiency Virus • Infectious Disease
|
|
Andrew Purssell; Jonathan B Angel; Kennedy Leung; Pierre Giguere
|